KIR2DL3 antibody

Catalog No. ABIN2688999

Product Details anti-KIR2DL3 Antibody

Target: KIR2DL3 (Killer Cell Immunoglobulin-Like Receptor, Two Domains, Long Cytoplasmic Tail, 3 (KIR2DL3))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This KIR2DL3 antibody is un-conjugated

Application: Flow Cytometry (FACS)

Brand: BD Pharmingen™

Characteristics: Reacts with a 50 - 58 kDa type I glycoprotein molecule of the killer cell inhibitory receptor (KIR) family of proteins. CD158b has also been known as GLI83, p50.2, or p58.2. CD158b is composed of two extracellular Ig-like domains. It is expressed on a subset of NK cells and it may also be present on rare T cells (either CD3/TCR αβ+, or CD3/TCR γδ+). CD158b regulates NK cell mediated cytolytic activity by interacting with HLA-C alleles (Cw 1, 3, 7 and 8). This antibody is routinely tested by flow cytometric analysis. Other applications were tested during antibody development only or reported in the literature. Profile of peripheral blood lymphocytes analyzed by flow cytometry

BD Pharmingen™ Purified Mouse Anti-Human CD158b - Purified - Clone CH-L - Isotype Mouse IgG2b, κ - Reactivity Hu - 0.1 mg

Purification: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Clone: CH

Isotype: IgG2b kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: Aqueous buffered solution containing ≤0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: Store undiluted at 4°C.

References for anti-KIR2DL3 antibody (ABIN2688999)

Kim, Chwae, Kim, Choi, Park, Kim: "Molecular basis of HLA-C recognition by p58 natural killer cell inhibitory receptors." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 159, Issue 8, pp. 3875-82, (1997) (PubMed).

Cambiaggi, Orengo, Meazza, Sforzini, Tazzari, Lauria, Raspadori, Zambello, Semenzato, Moretta, Ferrini: "The natural killer-related receptor for HLA-C expressed on T cells from CD3+ lymphoproliferative disease of granular lymphocytes displays either inhibitory or stimulatory function." in: Blood, Vol. 87, Issue 6, pp. 2369-75, (1996) (PubMed).

Colonna, Samaridis: "Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells." in: Science (New York, N.Y.), Vol. 268, Issue 5209, pp. 405-8, (1995) (PubMed).

Ferrini, Cambiaggi, Meazza, Sforzini, Marciano, Mingari, Moretta: "T cell clones expressing the natural killer cell-related p58 receptor molecule display heterogeneity in phenotypic properties and p58 function." in: European journal of immunology, Vol. 24, Issue 10, pp. 2294-8, (1994) (PubMed).

Target Details for KIR2DL3

Target: KIR2DL3 (Killer Cell Immunoglobulin-Like Receptor, Two Domains, Long Cytoplasmic Tail, 3 (KIR2DL3))

Alternative Name: CD158b (KIR2DL3 Products)

Synonyms: CD158B2 antibody, CD158b antibody, GL183 antibody, KIR-023GB antibody, KIR-K7b antibody, KIR-K7c antibody, KIRCL23 antibody, NKAT antibody, NKAT2 antibody, NKAT2A antibody, NKAT2B antibody, p58 antibody, killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 antibody, KIR2DL3 antibody

Pathways: Cancer Immune Checkpoints